Nephros, Inc. (NEPH) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with significant revenue growth and improved profitability. While there are risks such as regulatory challenges and supply chain costs, the company's operational discipline and strategic expansion efforts are promising. The Q&A section suggests a sustainable growth model and effective resource allocation. Despite the need for sales force expansion, the overall sentiment remains positive due to strong financial metrics and optimistic guidance.
Key Financial Performance
Trailing 12-month revenue $16.7 million, up from $13.8 million, reflecting strong operational execution and customer growth.
Q2 2025 Net Revenue $4.4 million, a 36% increase year-over-year, driven by growth in programmatic and emergency response businesses.
First Half 2025 Revenue $9.3 million, a 37% increase year-over-year, attributed to strong performance across all regions and programmatic business growth.
Gross Margins (Q2 2025) 63%, up from 59% in Q2 2024, due to reduced shipping costs and inventory reserve adjustments.
Research and Development Expenses (Q2 2025) $311,000, up from $254,000 in Q2 2024, due to increased headcount.
Sales, General and Administrative Expenses (Q2 2025) $2.2 million, up 13% from $1.9 million in Q2 2024, driven by higher sales commissions, employee bonuses, and stock compensation expenses.
Net Income (Q2 2025) $237,000, compared to a net loss of $289,000 in Q2 2024, reflecting improved profitability.
Adjusted EBITDA (Q2 2025) $355,000, compared to a loss of $133,000 in Q2 2024, indicating better operational performance.
Net Cash Provided by Operating Activities (Q2 2025) $994,000, an improvement of $1.495 million from the prior year, driven by positive net income, decreased accounts receivable, and increased accrued expenses.
First Half 2025 Gross Margins 64%, up from 61% in the prior year, due to favorable product mix and reduced inventory reserve adjustments.
First Half 2025 Net Income $795,000, compared to a net loss of $458,000 in the prior year, reflecting strong revenue growth and cost management.
First Half 2025 Adjusted EBITDA $1.022 million, compared to a loss of $228,000 in the prior year, showing improved financial performance.
Cash Balance (June 30, 2025) $5.1 million, up from $3.8 million as of December 31, 2024, with the company remaining debt-free.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
S100 microfilter and 20-inch HydraGuard: These new products have unlocked opportunities across cell processing, labs, and beyond.
Expansion into underserved verticals: Focused on dental, government, and municipal facilities.
Revenue growth: Trailing 12-month revenue grew from $13.8 million to $16.7 million, with Q2 revenue at $4.4 million, a 36% increase over Q2 2024.
Profitability: Achieved third consecutive quarter of profitability with net income of $237,000 in Q2 2025.
Gross margins: Improved to 63% in Q2 2025 from 59% in Q2 2024, driven by reduced shipping costs and inventory reserve adjustments.
Customer base: Active customer sites grew to over 1,600, with the highest retention rate in the past 6 quarters.
Cash flow: Net cash provided by operating activities was $994,000 in Q2 2025, an improvement of $1.495 million compared to Q2 2024.
Sales team expansion: Strategic expansion into non-healthcare verticals has started yielding results.
Filter tracking app: Increased customer adoption has improved visibility, compliance, and support, with thousands of filters now being tracked.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Requirements: The company faces challenges related to existing and new regulatory requirements, which could impact its business operations and compliance costs.
Market Adoption: The rate of adoption of the company's products and services by hospitals and other healthcare providers remains a critical factor for success, posing a risk if adoption rates slow.
Commercialization Efforts: The success of commercialization efforts is essential, and any failure in these efforts could adversely affect revenue growth and market penetration.
Economic and Competitive Factors: Economic uncertainties and competitive pressures in the market could negatively impact the company's performance and strategic objectives.
Operational Discipline: Maintaining operational discipline while scaling and protecting profitability is a challenge that could affect the company's financial stability.
Supply Chain Costs: Although shipping costs have decreased, any future increases in supply chain costs could impact gross margins and profitability.
R&D Expenses: Increased research and development expenses due to higher headcount could strain financial resources if not managed effectively.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Expansion into underserved verticals: The company plans to expand into underserved verticals such as dental, government, and municipal facilities.
New product innovations: Nephros is bringing new innovations to market, including the S100 microfilter and 20-inch HydraGuard, which are expected to unlock opportunities across cell processing, labs, and other areas.
Operational discipline and profitability: The company aims to execute with operational discipline while continuing to protect profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Where do you attribute the bulk of the growth in the quarter? Is it evenly divided among initiatives like the installation and replacement program, the app, or the expanded sales force?
A:The growth is attributed to a combination of the app, service capabilities, and the sales team. The app raised visibility of filter usage, the service capabilities turned visibility into action by helping customers replace filters, and the sales team maintained strong customer relationships. This deliberate and intentional growth model is sustainable.
Q:Do you believe you have a sufficient sales force to maintain current active customer sites and pursue growth in verticals outside of healthcare?
A:The company does not have a sufficient sales force in every location to grow. They have been strategic in deploying resources and are expanding into new areas through education and outreach. They are using a model where existing staff cover current needs while junior associates support operations, allowing seasoned experts to pursue new business. This model has been effective, but further expansion of the sales force is necessary.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. The management provided detailed and direct answers to all questions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisory Conference
CEO Director
Capital Group
Conference comment
Contents conference
Director McGovern
ET day
Form afternoon
Group LLC
HydraGuard opportunity
Krandel financials
LLC Conference
McGovern Unidentified
ProActive Capital
Relations Contents
Sales month
Smith ProActive
Unidentified Smith
account increase
account inventory
accrual employee
customer site
expense income
income loss
increase period
inventory reserve
period cash
period emergency
period increase
period loss
reduction
reserve adjustment
result filing
sale commission
vertical
year
NEPH Transcript
Nephros, Inc. (NEPH) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call presents a mixed picture. Financial performance shows positive trends with revenue growth and improved margins, but risks in marketing, sales, and regulatory compliance temper this optimism. The absence of strategic updates and shareholder return plans, alongside uncertainties in commercialization and economic factors, suggest a cautious outlook. Without further insights from the Q&A, the overall sentiment remains neutral.
Nephros, Inc. (NEPH) Q4 2025 Earnings Call Transcript
Positive3-12
Nephros reported strong revenue growth of 33% and improved net income and adjusted EBITDA, despite challenges like tariff impacts and increased R&D and SG&A expenses. The company's expansion into new markets and strong customer retention are promising. However, the Q&A section revealed some vagueness in management's responses, which could be a concern. Overall, the strong financial performance and strategic growth initiatives outweigh the negatives, suggesting a positive stock price movement.
Nephros, Inc. (NEPH) Q3 2025 Earnings Call Transcript
Positive11-7
Nephros shows strong financial performance with significant improvements in net income and adjusted EBITDA. The strategic expansion into underserved markets, innovative product launches, and maintaining a solid cash position are positive indicators. The Q&A highlights growth drivers in infection control and innovations tackling PFAS and microplastics, with a positive outlook on margins despite tariffs. However, lack of specific guidance on PFAS revenue and tariff impacts slightly tempers enthusiasm. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
Nephros, Inc. (NEPH) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call highlights strong financial performance with significant revenue growth and improved profitability. While there are risks such as regulatory challenges and supply chain costs, the company's operational discipline and strategic expansion efforts are promising. The Q&A section suggests a sustainable growth model and effective resource allocation. Despite the need for sales force expansion, the overall sentiment remains positive due to strong financial metrics and optimistic guidance.
NEPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
